Calithera Biosciences, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering and advancing small molecule compounds. Operating within the United States, their research and development efforts are primarily directed towards targets involved in tumor metabolism and immunology, with the ultimate goal of cancer treatment. Among its key pipeline assets is INCB001158, an arginase inhibitor designed for oral administration, currently progressing through Phase 1/2 clinical trials for various hematological and oncological indications. Another compound, CB-280, an oral arginase inhibitor, has successfully completed Phase 1b clinical trials, targeting cystic fibrosis and chronic airway infections. The company is also developing ATG-037, an orally bioavailable small molecule that inhibits CD73, and CB-668, an orally delivered inhibitor of the enzyme IL4I1. Calithera has forged several strategic alliances. It maintains a licensing agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for human health applications. A collaborative clinical trial with Pfizer is underway to assess the combined effects of telaglenasta with Pfizer's PARP inhibitor, talazoparib, and its CDK4/6 inhibitor, palbociclib. Additionally, a collaboration and license agreement with Incyte Corporation pertains to the research, development, and eventual market launch of INCB001158 for hematological and oncological treatments. Finally, a licensing deal with Antengene Corporation Ltd. focuses on the development and commercialization of CB-708. Founded in 2010, Calithera Biosciences, Inc. is headquartered in South San Francisco, California.